Our Company

Driven by science and discovery, connected by a passion to help patients

From Concept to Commercialization,
We Journey With You

We meet our partners where they are in the product life cycle and enable their work with our array of technology platforms, end-to-end capabilities and industry insights so they can bring their original concepts to commercialization.

Our Story

Building a first-of-its kind offering of enabling technologies and end-to-end capabilities to advance the work of the entire cell and gene therapy industry

2017 - Founded. David Hallal, Mitchell Finer and Vikas Sinha ask the question: what could be revolutionary in the next 30 to 50 years? ElevateBio formed in stealth mode.
September 2018. AlloVir, a leading innovator of allogeneic, multi-virus, t-cell immunotherapies, is added as a portfolio company.
May 2019. ElevateBio raises $150M in Series A financing, officially launching to create and operate a portfolio of highly innovative cell and gene therapy companies.
July 2019. Massachusetts General Hospital & Elevate announce strategic partnership.
October 2019. ElevateBio establishes and launches HighPassBio, a company dedicated to advancing novel targeted T cell immunotherapies initially developed by researchers at Fred Hutchinson Cancer Research Center.
January 2020. ElevateBio BaseCamp process development labs open, providing the tools and environment to accelerate cell and gene therapies.
March 2020. ElevateBio raises $170M in series B financing.
November 2020. LifeEdit, with it's novel Gene editing platform, is added as a portfolio company.
April 2021. BaseCamp is selected as 2021 Facility of the Year Award for Operational Excellence.
June 2021. Boston Children's Hospital and ElevateBio announce 5 Year Cell and Gene Therapy Collaboration.
October 2021. LifeEdit acquisition completed as ElevateBio accelerates genome editing platform.
October 2021. LifeEdit acquisition completed as ElevateBio accelerates genome editing platform.
August 2022: Formed long-term partnership with the University of Pittsburgh to locate a BaseCamp process development and GMP manufacturing facility at Hazelwood Green in Pittsburgh to accelerate cell and gene therapy innovation

Meet Our Team
of Industry Experts

Our team of world-class scientists, builders and operators use their deep industry expertise to equip our partners every step of the way.

Partner With Us

Wherever you are in your cell and gene therapy (CGT) product life cycle, we come alongside you to strengthen and accelerate the development of life-transformative CGTs.